Compound Labs / United States
Olympia Pharmacy
Compounding pharmacy in Orlando, Florida, United States. Listed, not endorsed.
Peptides Olympia Pharmacy names publicly
None named on its public pages.
Its site refers to peptides without naming them. A clinic information sheet that cites it names sermorelin.
Licence and status, as stated
Operates a 503A pharmacy and a 503B outsourcing facility. Lists LegitScript and NABP.
Who it supplies
Patients (503A), practitioners and central-fill pharmacies.
Public regulator records
- 2025-08-08: FDA published a Form 483 inspection record. Earlier Form 483s date from 2013 and 2018, and the FDA issued a warning letter in 2016. Source
Stated as dated public records. They are not a judgement of the pharmacy today.
The rules in the United States
A 503A pharmacy compounds against a prescription for a named patient and is regulated by its state pharmacy board. A 503B outsourcing facility registers with the FDA, follows current good manufacturing practice (cGMP) and can supply clinics with stock for use in the office. Several firms hold both. The wellness peptides on this page (sermorelin, GHK-Cu, gonadorelin) come from the 503A side of those firms.
Whether a substance can be compounded at all depends on the FDA's bulk drug substances lists. Ipamorelin, GHRP-2, GHRP-6 and kisspeptin-10 remain on the FDA's Category 2 list of substances that may present significant safety risks. Nominations for BPC-157, TB-500, CJC-1295, GHK-Cu, thymosin alpha-1 and others were withdrawn, and the FDA page was last updated on 22 April 2026. A withdrawn nomination does not make a substance approved.
On 23 and 24 July 2026 an FDA advisory committee voted to add six peptides, including BPC-157, to the 503A bulks list. Those votes are not binding until the FDA completes rulemaking. Compounding of GLP-1 drugs on shortage grounds ended in 2025, and the FDA now pursues compounded products that are "essentially copies" of approved drugs.